Nelumal A, the Active Principle of Ligularia nelumbifolia, is a Novel Aromatase Inhibitor

被引:0
|
作者
Epifano, Francesco [1 ]
Genovese, Salvatore [1 ]
Fiorito, Serena [1 ]
Nde, Chantal Magne [2 ]
Clyne, Colin [2 ,3 ]
机构
[1] Univ G dAnnunzio, Dept Pharm, I-66100 Chieti, CH, Italy
[2] Prince Henrys Inst Med Res, Canc Drug Discovery Lab, Clayton, Vic 3168, Australia
[3] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia
关键词
Aromatase inhibitors; Ligularia nelumbifolia; Nelumal A; Oxyprenylated secondary metabolites;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nelumal A, the active principle of Ligularia nelumbifolia was preliminarily tested as an aromatase inhibitors in HEK293 cells trartsfected with aromatase cDNA and using anastrazole as the reference drug. This screening revealed that it showed an appreciable level of inhibition. Subsequent experiments aimed to evaluate the aromatase activity and expression in KGN cells confirmed that the title natural product, after an incubation of 48 h, compared favourably with artastrazole (1 mu M) in the concentration range 10 - 30 mu M. Moreover, nelumal A (30 mu M) abolished the aromatase mRNA expression in the same cell line.
引用
收藏
页码:823 / 824
页数:2
相关论文
共 50 条
  • [21] The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma
    Gillam, MP
    Middler, S
    Freed, DJ
    Molitch, ME
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10): : 4447 - 4451
  • [22] Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
    Tannir, Nizar M.
    Schwab, Gisela
    Gruenwald, Viktor
    CURRENT ONCOLOGY REPORTS, 2017, 19 (02)
  • [23] Pharmacological characterization of a novel orally active neutrophil elastase inhibitor
    Kuromiya, A
    Okazaki, H
    Tsuji, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2691 - U2692
  • [24] Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
    Nizar M. Tannir
    Gisela Schwab
    Viktor Grünwald
    Current Oncology Reports, 2017, 19
  • [25] Pharmacology of a Novel, Orally Active PDE4 Inhibitor
    Dastidar, Sunanda G.
    Ray, Abhijit
    Shirumalla, Rajkumar
    Rajagopal, Deepa
    Chaudhary, Shiwani
    Nanda, Kamna
    Sharma, Pawan
    Seth, Mahesh Kumar
    Balachandran, Sarala
    Gupta, Nidhi
    Palle, Venkata
    PHARMACOLOGY, 2009, 83 (05) : 275 - 286
  • [26] A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase
    Giardina, Sarah F.
    Werner, Douglas S.
    Pingle, Maneesh
    Bergstrom, Donald E.
    Arnold, Lee D.
    Barany, Francis
    PHARMACOLOGY, 2018, 102 (5-6) : 233 - 243
  • [27] A Novel Active Online Electromagnetic Balancing Method-Principle and Structure Analysis
    Ma, Shilei
    Pei, Shiyuan
    Wang, Lin
    Xu, Hua
    JOURNAL OF VIBRATION AND ACOUSTICS-TRANSACTIONS OF THE ASME, 2012, 134 (03):
  • [28] CYP1A2-A novel genetic marker for aromatase inhibitor response in the treatment of breast cancer patients
    Simonsson, M.
    Veerla, S.
    Markkula, A.
    Rose, C.
    Ingvar, C.
    Jernstrom, H.
    CANCER RESEARCH, 2016, 76
  • [29] A novel phytoalexin, glyceollins, trigger anti-proliferative effects in aromatase inhibitor resistant breast cancer cells
    Walker, Rashidra R.
    Patel, Jankiben
    Davidson, A. Michael
    Gallegos, Karen
    Tilghman, Syreeta L.
    CANCER RESEARCH, 2020, 80 (04)
  • [30] A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects
    Ahokoski, O
    Irjala, K
    Huhtala, S
    Salminen, E
    Scheinin, H
    Huupponen, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) : 27 - 34